King Pharmaceuticals | search
Click here to view King Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- KING PHARMACEUTICALS, INC. - Quote Nyse- MarketScreenerKing Pharmaceuticals, Inc. (KG.NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock King Pharmaceuticals, Inc. | Nyse: KG | Nyse.
- Pfizer buys King Pharmaceuticals for $3.6 billionKnown primarily for its tamper-resistant formulations of opioid analgesics, King Pharmaceuticals will expand Pfizer's portfolio in the pain category, adding King's Embeda, Avinza and Flector Patch to Pfizer's Lyrica and Celebrex products.
- Pfizer to Acquire King Pharmaceuticals, Inc.Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing price as of October.
- King Pharmaceuticals, Inc. -- Company HistoryKing Pharmaceuticals, Inc. is a Bristol, Tennessee, company that has leveraged its position as a contract manufacturer of drugs to become a significant niche player in the pharmaceutical industry.
- Pfizer Completes Acquisition Of King Pharmaceuticals, Inc.(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King.
More
